Iovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Iovance Biotherapeutics (NASDAQ:IOVA) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Other analysts have also issued reports about the company. Chardan Capital dropped their target price on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday. Barclays boosted their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Wednesday. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Finally, Citizens Jmp raised shares of Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Wednesday. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Iovance Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $9.33.

Iovance Biotherapeutics Price Performance

NASDAQ IOVA opened at $3.86 on Friday. The firm’s fifty day moving average price is $2.72 and its 200 day moving average price is $2.43. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $4.57. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -3.45 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $86.77 million for the quarter, compared to analyst estimates of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. As a group, sell-side analysts forecast that Iovance Biotherapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its position in shares of Iovance Biotherapeutics by 161.2% in the first quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company’s stock valued at $1,740,000 after purchasing an additional 322,680 shares in the last quarter. AQR Capital Management LLC raised its position in Iovance Biotherapeutics by 279.0% in the 1st quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 43,829 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Iovance Biotherapeutics by 30.5% during the first quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock worth $18,554,000 after purchasing an additional 1,301,846 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Iovance Biotherapeutics by 202.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock valued at $19,239,000 after buying an additional 3,869,617 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Iovance Biotherapeutics by 112.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 25,083 shares during the period. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q4 / FY results beat expectations — Iovance reported Q4 product revenue of ~$87M (30% growth Q/Q) and full‑year revenue up ~61% to ~$264M; GAAP EPS was less negative than expected (Q4 EPS roughly -$0.18 vs. consensus -$0.22). Investors are treating the print as evidence that Amtagvi commercial sales and the company’s growth trajectory are real. IOVA Beats on Q4 Earnings & Sales
• Positive Sentiment: Pipeline and development catalysts — the stock popped on 50% ORR data and Iovance’s plan for a registrational sarcoma study, reinforcing upside from clinical progress beyond commercial sales. That data-driven message contributed materially to today’s buying. Pipeline Progress & ORR Data
• Positive Sentiment: Analyst upgrades and estimate lifts — HC Wainwright raised FY2026/FY2027 EPS assumptions and maintains a Buy/$9 target; Citizens JMP upgraded Iovance to Outperform. Upgrades and higher price targets amplify demand from institutions and momentum traders. Raised to Outperform at Citizens Jmp
• Positive Sentiment: Manufacturing/commercial ramp explained — reporting and coverage highlighted the Philadelphia factory ramp as a key reason sales can scale, reducing execution risk around supply and supporting the narrative that Iovance is transitioning from pure pipeline to a commercial-stage company. Philadelphia Factory Explains Surge
• Neutral Sentiment: High trading and options activity — unusually large options and stock volume signaled speculative interest and positioning around the earnings/catalyst news; this can amplify intraday moves but is not a sustained fundamental change by itself. Unusually Large Options Volume
• Neutral Sentiment: Management investor outreach — Iovance announced presentations at TD Cowen and Barclays conferences (early March), which could provide additional color but are routine post‑earnings investor engagement. Conference Presentations
• Negative Sentiment: Very large and rising short interest — short interest jumped ~24.8% to ~131M shares (~36.9% of float) with a ~14.6 day cover ratio, leaving the stock vulnerable to volatility and squeezes; this elevated shorting is both a risk (pressure on future upside if sentiment reverses) and a potential amplifier of rapid moves. (data reported 2/25)

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.